Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : COVID-19 hot spot mayors want shorter dose interval for AstraZeneca recipients

06/11/2021 | 03:09pm EDT

TORONTO — Mayors in an Ontario COVID-19 hot spot are joining calls for the government to reduce the vaccine dosing interval for Oxford-AstraZeneca recipients as a more infectious variant spreads in the province.

Residents who got a first shot of AstraZeneca currently must wait 12 weeks between doses in Ontario, but other provinces have shortened the gap to eight weeks.

Brampton Mayor Patrick Brown wrote to the premier and health minister on Friday asking that Ontario follow suit with an eight-week gap between doses.

"Residents should have the choice to be fully immunized sooner so they have better protection against variants," wrote Brown, whose community is part of Peel Region, where the Delta variant has been spreading. "Help us crush COVID in Peel!"

Brown's Mississauga counterpart, Mayor Bonnie Crombie, also wrote a letter calling for a shorter dose interval. She said residents who took a first shot of the AstraZeneca vaccine helped curb the third wave of COVID-19 and are now being left less protected.

"They are watching family members and friends register (for) and receive second doses, and it is simply not fair," Crombie wrote in her letter Friday.

Calls have been growing for Ontario to shorten the dosing interval for AstraZeneca recipients as the more infectious Delta variant spreads. Doctors, politicians and those who got AstraZeneca have been urging the government to change its position.

Scientific evidence shows people with one vaccine dose are less protected against the Delta variant.

An online petition asking the government to shorten the interval to eight weeks for those who got AstraZeneca had more than 2,800 signatures as of Friday afternoon.

Gareth Williams of Burlington, Ont., said he started the petition after he grew frustrated watching second shots get moved up for others.

"We seem to be forgotten," Williams said by phone.

"I think a lot of people are in the same boat as me. They got it themselves and a lot of other people who have family members that have received it and are frustrated."

Starting Monday, residents of seven Delta variant hot spots who got a first dose of a COVID-19 vaccine on or before May 9 and book accelerated second doses. Those aged 70 and older can already book faster second shots.

AstraZeneca recipients, however, must still wait 12 weeks for their second shot, whether they opt for another dose of the same vaccine or a shot of a mRNA vaccine.

Ontario has maintained that 12 weeks is the most effective dosing interval for AstraZeneca, with Health Minister Christine Elliott calling it the "gold standard" on Thursday.

The province's associate chief medical officer of health has noted, however, that the province is reviewing data on the issue.

"We're very actively looking now at the data with Public Health Ontario and are actively considering the intervals for those individuals," Dr. Barbara Yaffe said Thursday.

The head of the Ontario Pharmacists Association said AstraZeneca recipients should be able to choose whether to get an earlier second shot in light of the spreading Delta variant or wait for 12 weeks to become fully vaccinated.

"The benefit of getting people fully vaccinated outweighs any potential decrease in optimal efficacy," Justin Bates wrote on Twitter.

Ontario stopped administering first doses of AstraZeneca in May over what it said was an increased risk of rare but serious blood clots. It had given out nearly a million doses of the vaccine by that point.

- With files from Denise Paglinawan.

This report by The Canadian Press was first published June 11, 2021.

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about ASTRAZENECA PLC
04:22pTHE LATEST : Israel delays reopening of borders to tourists
AQ
10:39aGENPREX  : to Move Forward With Phase 1/2 Trial of Lung Cancer Combo Therapy
MT
10:16aGLOBAL MARKETS LIVE : Microsoft, Morgan Stanley, Heineken, Twitter, AstraZeneca...
09:25aSTREET COLOR : Two US House Panels Seeking Details on Emergent Relationship Betw..
MT
08:57aGenprex Shares Rise 8% on FDA Review of Reqorsa Trial
DJ
06:49aASTRAZENECA  : First-in-class approval in China in this setting and first regula..
PU
04:17aASTRAZENECA  : Receives Conditional Approval in China for Lung Cancer Treatment
MT
02:11aDebate Intensifies Over A Vaccine IP Waiver's Impact On Future Pharma And Bio..
AQ
02:05aASTRAZENECA  : Orpathys approved in China for patients with lung cancer and MET ..
PU
01:39aASTRAZENECA  : What you need to know about the coronavirus right now
RE
More news
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,7x
Yield 2021 2,45%
Capitalization 152 B 153 B -
EV / Sales 2021 5,26x
EV / Sales 2022 4,54x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 116,46 $
Average target price 132,57 $
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.01%152 574
JOHNSON & JOHNSON3.96%430 876
ROCHE HOLDING AG11.75%324 905
PFIZER, INC.7.61%221 725
NOVARTIS AG2.56%209 282
ABBVIE INC.7.05%202 586